

**Online Supplementary File 1.** Cancer site, ICD10 code, and applied tumour grouping for analysis.

<b>Subsite malignant cancer</b>	<b>ICD10 code</b>	<b>Tumor type</b>	<b>Pelvis/nonpelvis</b>	<b>Region</b>
<b>Lip, oral cavity and pharynx</b>	C0-C14		Nonpelvis	
<b>Nasal cavity, middle ear, sinuses</b>	C30,C31		nonpelvis	
<b>Larynx</b>	C32		nonpelvis	
<b>Eye and adnexa</b>	C69		nonpelvis	
<b>Meninges</b>	C70	Central Nervous System	nonpelvis	
<b>Brain</b>	C71	Central Nervous System	nonpelvis	
<b>Pineal Gland</b>	C75	Central Nervous System	nonpelvis	
<b>Spinal cord/other parts CNS</b>	C72	Central Nervous System	nonpelvis	
<b>Thyroid gland</b>	C73		nonpelvis	
<b>Esophagus</b>	C15	gastrointestinal	nonpelvis	chest
<b>Stomach</b>	C16	gastrointestinal	nonpelvis	abdomen
<b>Small Intestine</b>	C17	gastrointestinal	nonpelvis	abdomen
<b>Colon</b>	C18	gastrointestinal	nonpelvis	abdomen
<b>Appendix</b>	C18.1	gastrointestinal	nonpelvis	abdomen
<b>Rectum + rectosigmoid</b>	C19,C20	gastrointestinal	pelvis	pelvis
<b>Anus, anal canal</b>	C21	gastrointestinal	pelvis	pelvis
<b>Liver, gallbladder &amp; billiary tract</b>	C22-C24	gastrointestinal	nonpelvis	abdomen
<b>Pancreas</b>	C25	gastrointestinal	nonpelvis	abdomen
<b>Penis</b>	C60	genitourinary tract	pelvis	pelvis
<b>Testis &amp; other male genitalia</b>	C62,C63	genitourinary tract	pelvis	pelvis
<b>Kidney</b>	C64	genitourinary tract	nonpelvis	abdomen
<b>Renal pelvis</b>	C65	genitourinary tract	nonpelvis	abdomen
<b>Bladder</b>	C67	genitourinary tract	pelvis	pelvis
<b>Ureter</b>	C66	genitourinary tract	nonpelvis	abdomen
<b>Urethra</b>	C68	genitourinary tract	pelvis	pelvis

<b>Trachea</b>	C33		nonpelvis	chest
<b>Lung &amp; bronchus</b>	C34		nonpelvis	chest
<b>Heart, mediastinum, pleura</b>	C38		nonpelvis	chest
<b>Pleuramesothelioma</b>	C38.4		nonpelvis	chest
<b>Thymus</b>	C37		nonpelvis	chest
<b>Breast</b>	C50		nonpelvis	chest
<b>Bone limbs</b>	C40		nonpelvis	
<b>Pelvic bones</b>	C41.4		pelvis	pelvis
<b>Other bones</b>	C41.0/1/2/3/8/9		nonpelvis	
<b>Kaposi sarcoma</b>	C46	soft tissue	nonpelvis	
<b>Peripheral nervous system</b>	C47	soft tissue	nonpelvis	
<b>(Retro)peritoneum</b>	C48	soft tissue	nonpelvis	abdomen
<b>Other soft tissue - headneck</b>	C49.0	soft tissue	nonpelvis	
<b>Other soft tissue - limbs</b>	C49.1, C49.2	soft tissue	nonpelvis	
<b>Other soft tissue - thorax</b>	C49.3	soft tissue	nonpelvis	chest
<b>Other soft tissue - abdomen</b>	C49.4	soft tissue	nonpelvis	abdomen
<b>Other soft tissue - pelvis</b>	C49.5	soft tissue	pelvis	pelvis
<b>Other soft tissue - unspecified/overlap</b>	C49.6-C49.9	soft tissue	nonpelvis	
<b>Unknown primary -description pelvis</b>	C80		pelvis	pelvis
<b>Unknown primary - unclear/outside pelvis</b>	C80		nonpelvis	

**Online Supplementary File 2.** Estimated sHRs (sensitivity analysis) when other treatment-related factors are added to the baseline model (age, calendar period, technique) for the primary endpoint of non-pelvic second primary cancer. Abbreviations: sHR = subhazard ratio, CI=confidence interval.

Treatment characteristic	Fine & Gray Model		Estimated sHR for IMRT vs 3DCRT
	sHR additional factor (95% CI)	p-value	
Baseline model	-		1.56
+Seminal vesicle dose ≥50 Gy vs 0 Gy	0.97 (0.66-1.42)	0.9	1.56
+Prostate dose 78 Gy vs 72 Gy	0.94 (0.58-1.54)	0.8	1.57
+Hormonal therapy yes vs no	0.90 (0.66-1.22)	0.5	1.57
+Setup verification online vs offline	1.04 (0.59-1.86)	0.9	1.52
Baseline model for 78 Gy subgroup only			1.53